PFE
Pfizer Inc
Q4 2024 Report
Pfizer Inc (PFE) Q4 2024 Financial Results: Strong Revenue Growth Amid Strategic Portfolio Transformations...
Read full report
Executive Summary
Pfizer Inc reported a solid start to Q1 2024, achieving total revenues of $14.9 billion. Excluding contributions from COVID-19 products, the company witnessed an operational revenue growth of 11%. CEO Albert Bourla emphasized progress in oncology and pipeline innovation while cautioning about the ongoing impacts of declining COVID revenues. The adjusted diluted EPS rose to $0.82, surpassing expectations due to favorable gross margin performance and stringent cost management. The performance reflects strong market demand for new oncology products, notably PADCEV and XTANDI, alongside successful vaccine initiatives. However, with the strong quarter comes caution regarding the full-year outlook due to continuing inflationary pressures and anticipated shifts in the vaccine market.
Key Performance Indicators
Revenue
14.88B
QoQ: 4.42% | YoY:16.84%
Gross Profit
10.50B
70.60% margin
QoQ: 85.58% | YoY:28.98%
Operating Income
4.56B
QoQ: 386.19% | YoY:119.39%
Net Income
3.12B
QoQ: 193.15% | YoY:33.86%
EPS
0.55
QoQ: 193.22% | YoY:34.15%
Revenue Trend
Margin Analysis
Key Insights
- **Total Revenue**: $14.9 billion, operational decline of 19% YoY driven primarily by lower demand for COVID-19 treatments; when excluding COVID products, revenues grew 11%. ### Profitability Metrics
- **Gross Profit**: $10.5 billion; gross margin improved to 79.6%, up 530 basis points driven by favorable sales mix and cost management.
- **Operating Income**: $4.56 billion; operating margin at 30.5%.
- **Net Income**: $3.12 billion with net income margin at 20.9%. ### Earnings Per Share
- **EPS**: Reported at $0.55. Adjusted diluted EPS of $0.82 surpassed guidance expectations of $0.75.